Biomics Biopharma (ASX:BBM) LT-Debt-to-Total-Asset: 0.00 (As of . 20)


What is Biomics Biopharma LT-Debt-to-Total-Asset?

Biomics Biopharma ASX:BBM LT-Debt-to-Total-Asset is 0.00 as of . 20.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biomics Biopharma's long-term debt to total assests ratio for the quarter that ended in . 20 was 0.00.

Biomics Biopharma's long-term debt to total assets ratio stayed the same from . 20 (0.00) to . 20 (0.00).

Biomics Biopharma  (ASX:BBM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biomics Biopharma LT-Debt-to-Total-Asset Related Terms

Biomics Biopharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma LT-Debt-to-Total-Asset Chart

Biomics Biopharma Annual Data
Trend
LT-Debt-to-Total-Asset

Biomics Biopharma Semi-Annual Data
LT-Debt-to-Total-Asset

Biomics Biopharma LT-Debt-to-Total-Asset Calculation

Biomics Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Biomics Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in . 20 is calculated as

LT Debt to Total Assets (Q: . 20 )=Long-Term Debt & Capital Lease Obligation (Q: . 20 )/Total Assets (Q: . 20 )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Biomics Biopharma (ASX:BBM) has a LT-Debt-to-Total-Asset of 0.00 as of . 20. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's LT-Debt-to-Total-Asset too high?
Biomics Biopharma's current LT-Debt-to-Total-Asset is 0.00.
How does Biomics Biopharma's LT-Debt-to-Total-Asset compare to competitors?
Biomics Biopharma's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current LT-Debt-to-Total-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.